The blood test detected known mutations in 83 percent of the samples. Researchers there used more than 17,000 blood samples from patients diagnosed with 50 different types of cancer to see if a liquid biopsy test from Guardant Health (which paid for the study) would flag known mutations that drive cancer. Headlines about “liquid biopsies” and their ability to track cancer via a simple blood test cropped up soon after the conference opened its doors, thanks to a large new study presented by researchers at the University of California Davis Comprehensive Cancer Center. What were some of the other big takeaways at this year’s meeting, dubbed “Collective Wisdom: The Future of Patient-Centered Care and Research”? What’s cool but perhaps not quite ready for primetime? We turned to a handful of experts – online and off – to provide a bit of perspective. There was even news of a new drug that uses artificial intelligence to slow the growth of cancer. Hundreds of new findings and insights were presented during the five-day event in Chicago, covering all things cancer from biomarkers to big data, prevention to palliative care, survivorship to social media. Cameron Turtle regarding his recent work with CAR T-cell therapies in leukemia and lymphoma patients. Immunotherapy was one of the hottest topics there, with presentations on new therapies for lung cancer, metastatic melanoma, metastatic kidney cancer and much more, including exciting results from Fred Hutchinson Cancer Research Center’s Dr. The biggest cancer conference in the world, an annual meeting hosted by the American Society of Clinical Oncology that attracted more than 35,000 cancer researchers, oncologists, patient advocates, politicians and other major players in pharma and biotech, just closed its doors for another year. Diversity, Equity and Reduction of Health Disparities.Immunotherapy, Data Science, and the Steam Plant.Institutional Partners & Collaborations.Vaccine and Infectious Disease Division.

Cancer conference 2016 chicago